Biopharma has hyped AI for years. But as the first trials get underway, experts try to manage expectations

If you’re at all familiar with the biotech space, you’ve probably heard of the promises of artificial intelligence and machine learning.

These promises have been tantalizing. AI and ML can, proponents claim, help researchers speed along the arduous and expensive drug development process. By attempting to utilize algorithms and computing...

Click to view original post